Results 11 to 20 of about 692,862 (304)

Factors associated with β-blocker initiation and discontinuation in a population-based cohort of seniors newly diagnosed with heart failure

open access: yesPatient Preference and Adherence, 2016
Catherine Girouard,1–3 Jean-Pierre Grégoire,1–3 Paul Poirier,2,4 Jocelyne Moisan1–3 1Chair on Adherence to Treatments, Université Laval, 2Faculty of Pharmacy, Université Laval, 3Population Health and Optimal Health
Girouard C   +3 more
doaj   +1 more source

Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease

open access: yesInternational Journal of COPD, 2017
Naohiro Oda,1 Nobuaki Miyahara,1,2 Hirohisa Ichikawa,3 Yasushi Tanimoto,4 Kazuhiro Kajimoto,5 Makoto Sakugawa,6 Haruyuki Kawai,7 Akihiko Taniguchi,1 Daisuke Morichika,1 Mitsune Tanimoto,1 Arihiko Kanehiro,1 Katsuyuki Kiura1 1Department of Allergy and ...
Oda N   +11 more
doaj   +1 more source

Beta-blocker use and up-titration after acute ST-segment elevation myocardial infarction: a cohort study

open access: yesSwiss Medical Weekly, 2020
BACKGROUND The European Society of Cardiology recommends beta-blocker prescription after ST-segment elevation myocardial infarction (STEMI).
Christel Bruggmann   +5 more
doaj   +1 more source

Impact of beta‐blocker use on the long‐term outcomes of heart failure patients with chronic obstructive pulmonary disease

open access: yesESC Heart Failure, 2021
Aims The number of patients with both chronic obstructive pulmonary disease (COPD) and heart failure (HF) is increasing in Asia, and these conditions often coexist.
Yoshiaki Kubota   +13 more
doaj   +1 more source

Beta‐blocker use and mortality among patients with systolic heart failure and pacemaker rhythm

open access: yesESC Heart Failure, 2023
Aims Beta‐blockers are proven to improve survival among patients with heart failure with reduced ejection fraction. Their efficacy in patients with heart failure with reduced ejection fraction and pacemaker devices has not been demonstrated.
Andrew S. Perry   +3 more
doaj   +1 more source

Evaluation of beta-blocker effects on patients with traumatic brain injury: interventional double-blinded randomized controlled trial

open access: yesAin Shams Journal of Anesthesiology, 2023
Background Traumatic brain injury (TBI) is a major cause of death and disability throughout the world. Traumatic injury is one of the most common causes of death in people under the age of 40 worldwide, and one-third of all trauma-related deaths are a ...
Mostafa Saieed Mansour   +2 more
doaj   +1 more source

Influence of beta-blocker therapy on the risk of infections and death in patients at high risk for stroke induced immunodepression. [PDF]

open access: yesPLoS ONE, 2018
Stroke-induced immunodepression is a well characterized complication of acute ischemic stroke. In experimental studies beta-blocker therapy reversed stroke-induced immunodepression, reduced infection rates and mortality.
Ilko L Maier   +6 more
doaj   +1 more source

The β-blocker Nebivolol Is a GRK/β-arrestin Biased Agonist [PDF]

open access: yes, 2013
Nebivolol, a third generation β-adrenoceptor (β-AR) antagonist (β-blocker), causes vasodilation by inducing nitric oxide (NO) production. The mechanism via which nebivolol induces NO production remains unknown, resulting in the genesis of much of the ...
Jackson, Edwin K.   +36 more
core   +1 more source

Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients

open access: yesCardiovascular Diabetology, 2019
Background Although beta blockers could increase the risk of hypoglycemia, the difference between subtypes on hypoglycemia and mortality have not been studied.
Kathleen Dungan   +3 more
doaj   +1 more source

Evaluation of central: peripheral blood pressure ratio in patients undergoing coronary angiography: A pilot study from North India

open access: yesHeart India, 2020
Aim: The study aimed to propose the ratio of central blood pressure:peripheral blood pressure as a novel index to predict cardiovascular risk. We additionally attempted to determine the impact of beta-blocker therapy on this ratio. Materials and Methods:
Sharad Chandra   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy